HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Nominee McClellan Would Cement Agency’s Ties To Bush White House

This article was originally published in The Tan Sheet

Executive Summary

The nomination of White House advisor Mark McClellan, MD/PhD, as FDA commissioner ensures the agency will continue its close alignment with Bush Administration priorities

You may also be interested in...



Senate Health Committee Eyes October Hearing For McClellan

The Senate Health Committee appears to be fast-tracking the confirmation process for FDA commissioner nominee Mark McClellan, MD/PhD

FDA Commissioner McClellan? HHS’ Thompson Says Nomination Is Imminent

The Bush Administration appears ready to move forward with the nomination of health advisor Mark McClellan, MD/PhD, as FDA commissioner

White House Expands Reach Into FDA: Skladany Named External Affairs Head

New FDA Senior Associate Commissioner for External Relations Linda Skladany is a veteran of a half dozen political appointments in the Reagan/Bush Administration

Topics

UsernamePublicRestriction

Register

RS130318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel